Interferon lambda: Opportunities, risks, and uncertainties in the fight against HCV

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Laidlaw, Stephen M ^a   Dustin, Lynn B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chronic infection; Hepatitis C virus; Hepatocyte; Innate immunity; Interferon lambda

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD81 ANTIGEN; CLAUDIN 1; DACLATASVIR; GAMMA INTERFERON RECEPTOR; INTERFERON; INTERFERON LAMBDA; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; JANUS KINASE 1; LAMBDA INTERFERON RECEPTOR; LEDIPASVIR; MICRORNA 122; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PATTERN RECOGNITION RECEPTOR; RIBAVIRIN; SCAVENGER RECEPTOR BI; SOFOSBUVIR; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; CELL CULTURE; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INNATE IMMUNITY; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; REVIEW; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INHIBITION; VIRUS PATHOGENESIS;

EID: 84919422908     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00545     Document Type: Review

References (117)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 17:107-15. doi: 10.1111/j.1469-0691.2010.03432.x
2. Mutimer D, Aghemo A, Diepolder H, Negro F, Robaeys G, Ryder S, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol (2014) 60:392-420. doi:10.1016/j.jhep.2013.11.003
3. SeeffLB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 29(Suppl 1):89-99. doi:10.1111/j.1478-3231.2008.01927.x
4. Smith DB, Bukh J, Kuiken C, MuerhoffAS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 59:318-27. doi:10.1002/hep.26744
5. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 15:41-63. doi:10.1055/s-2007-1007262
6. Da Costa D, Turek M, Felmlee DJ, Girardi E, Pfeffer S, Long G, et al. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol (2012) 86:11919-25. doi:10.1128/JVI.01066-12
7. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 501:237-41. doi:10.1038/nature12427
8. Vogt A, Scull MA, Friling T, Horwitz JA, Donovan BM, Dorner M, et al. Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology (2013) 444:1-11. doi:10.1016/j.virol.2013.05.036
9. Frentzen A, Anggakusuma, Gurlevik E, Hueging K, Knocke S, Ginkel C, et al. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology (2014) 59:78-88. doi:10.1002/hep.26626
10. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science (2005) 309:1577-81. doi:10.1126/science.1113329
11. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J (2008) 27:3300-10. doi:10.1038/emboj.2008.244
12. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans (2008) 36:1220-3. doi:10.1042/BST0361220
13. Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, Michalak TI, et al. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J Virol (2010) 84:9170-80. doi:10.1128/JVI.00559-10
14. Machlin ES, Sarnow P, Sagan SM. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A (2011) 108:3193-8. doi:10.1073/pnas.1012464108
15. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol (2010) 84:6615-25. doi:10.1128/JVI.00417-10
16. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 76:13001-14. doi:10.1128/JVI.76.24.13001-13014.2002
17. Murray EM, Grobler JA, Markel EJ, Pagnoni MF, Paonessa G, Simon AJ, et al. Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol (2003) 77:2928-35. doi:10.1128/JVI.77.5.2928-2935.2003
18. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285:110-3. doi:10.1126/science.285.5424.110
19. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science (2005) 309:623-6. doi:10.1126/science.1114016
20. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 11:791-6. doi:10.1038/nm0805-905b
21. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 102:9294-9. doi:10.1073/pnas.0503596102
22. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol (2001) 64:334-9. doi:10.1002/jmv.1055
23. Ploss A, Khetani SR, Jones CT, Syder AJ, Trehan K, Gaysinskaya VA, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A (2010) 107:3141-5. doi:10.1073/pnas.0915130107
24. Podevin P, Carpentier A, Pene V, Aoudjehane L, Carriere M, Zaidi S, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 139:1355-64. doi:10.1053/j.gastro.2010.06.058
25. Gondeau C, Briolotti P, Razafy F, Duret C, Rubbo PA, Helle F, et al. In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model. Gut (2013) 63:1490-500. doi:10.1136/gutjnl-2013-304623
26. Helle F, Brochot E, Fournier C, Descamps V, Izquierdo L, Hoffmann TW, et al. Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PLoS One (2013) 8:e70809. doi:10.1371/journal.pone.0070809
27. Iacovacci S, Manzin A, Barca S, Sargiacomo M, Serafino A, Valli MB, et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology (1997) 26:1328-37. doi:10.1053/jhep.1997.v26.pm0009362380
28. Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol (2007) 170:478-89. doi:10.2353/ajpath.2007.060789
29. Andrus L, Marukian S, Jones CT, Catanese MT, Sheahan TP, Schoggins JW, et al. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology (2011) 54:1901-12. doi:10.1002/hep.24557
30. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, et al. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 54:1913-23. doi:10.1002/hep.24580
31. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe (2014) 15:190-202. doi:10.1016/j.chom.2014.01.007
32. Targett-Adams P, Boulant S, McLauchlan J. Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. J Virol (2008) 82:2182-95. doi:10.1128/JVI.01565-07
33. Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev (2011) 243:61-73. doi:10.1111/j.1600-065X.2011.01048.x
34. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 147:258-67. doi:10.1098/rspb.1957.0049
35. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci (1957) 147:268-73. doi:10.1098/rspb.1957.0049
36. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem (2007) 282:20053-7. doi:10.1074/jbc. R700006200
37. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 15:563-91. doi:10.1146/annurev.immunol.15.1.563
38. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol (2011) 1:519-25. doi:10.1016/j.coviro.2011.10.008
39. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2003) 4:69-77. doi:10.1038/ni875
40. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2003) 4:63-8. doi:10.1038/ni873
41. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 45:164-71. doi:10.1038/ng.2521
42. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res (2010) 30:555-64. doi:10.1089/jir.2010.0078
43. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J (2003) 370:391-6. doi:10.1042/BJ20021935
44. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J (2013) 32:3055-65. doi:10.1038/emboj.2013.232
45. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl 2014. Nucleic Acids Res (2014) 42:D749-55. doi:10.1093/nar/gkt1196
46. O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-lambda4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res (2014). doi:10.1089/jir.2013.0136
47. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4:e1000017. doi:10.1371/journal.ppat.1000017
48. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the JAK-STAT pathway and the mitogen-activated protein kinases. J Virol (2007) 81:7749-58. doi:10.1128/JVI.02438-06
49. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, et al. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One (2010) 5:e15200. doi:10.1371/journal.pone.0015200
50. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol (2013) 93:377-85. doi:10.1189/jlb.0812395
51. Hermant P, Demarez C, Mahlakoiv T, Staeheli P, Meuleman P, Michiels T. Human but not mouse hepatocytes respond to interferon-lambda in vivo. PLoS One (2014) 9:e87906. doi:10.1371/journal.pone.0087906
52. Au-Yeung N, Mandhana R, Horvath CM. Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. JAKSTAT (2013) 2:e23931. doi:10.4161/jkst.23931
53. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 279:32269-74. doi:10.1074/jbc. M404789200
54. Reich NC. STATs get their move on. JAKSTAT (2013) 2:e27080. doi:10.4161/jkst.27080
55. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 80:4501-9. doi:10.1128/JVI.80.9.4501-4509.2006
56. Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res (2006) 26:373-9. doi:10.1089/jir.2006.26.373
57. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 289:G960-8. doi:10.1152/ajpgi.00126.2005
58. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 44:896-906. doi:10.1002/hep.21312
59. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, Macdonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 131:1887-98. doi:10.1053/j.gastro.2006.09.052
60. Kohli A, Zhang X, Yang J, Russell RS, Donnelly RP, Sheikh F, et al. Distinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells. J Viral Hepat (2012) 19:843-53. doi:10.1111/j.1365-2893.2012.01610.x
61. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology (2012) 143(429-438):e428. doi:10.1053/j.gastro.2012.04.018
62. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology (2014) 59:1262-72. doi:10.1002/hep.26657
63. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun (2009) 10:125-31. doi:10.1038/gene.2008.87
64. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 31:109-18. doi:10.1016/j.cyto.2005.04.003
65. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat Immunol (2014) 15:717-26. doi:10.1038/ni.2915
66. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med (2010) 207:2703-17. doi:10.1084/jem.20092720
67. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol (2012) 189:2735-45. doi:10.4049/jimmunol.1102038
68. Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog (2013) 9:e1003316. doi:10.1371/journal.ppat.1003316
69. Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, et al. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One (2012) 7:e44915. doi:10.1371/journal.pone.0044915
70. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol (2011) 54:859-65. doi:10.1016/j.jhep.2010.08.020
71. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest (2004) 84:1148-59. doi:10.1038/labinvest.3700135
72. Lee HC, Narayanan S, Park SJ, Seong SY, Hahn YS. Transcriptional regulation of IFN-lambda genes in hepatitis C virus-infected hepatocytes via IRF-3.IRF-7.NF-kappaB complex. J Biol Chem (2014) 289:5310-9. doi:10.1074/jbc. M113.536102
73. Gad HH, Hamming OJ, Hartmann R. The structure of human interferon lambda and what it has taught us. J Interferon Cytokine Res (2010) 30:565-71. doi:10.1089/jir.2010.0062
74. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res (2000) 28:235-42. doi:10.1093/nar/28.1.235
75. Edgar RC. Muscle: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics (2004) 5:113. doi:10.1186/1471-2105-5-113
76. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem (2009) 284:20869-75. doi:10.1074/jbc. M109.002923
77. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, Wlodawer A. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J Mol Biol (2010) 404:650-64. doi:10.1016/j.jmb.2010.09.068
78. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol (2007) 179:3434-42. doi:10.4049/jimmunol.179.6.3434
79. Thomson SJ, Goh FG, Banks H, Krausgruber T, Kotenko SV, Foxwell BM, et al. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc Natl Acad Sci U S A (2009) 106:11564-9. doi:10.1073/pnas.0904477106
80. Griffiths SJ, Koegl M, Boutell C, Zenner HL, Crump CM, Pica F, et al. A systematic analysis of host factors reveals a Med23-interferon-lambda regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog (2013) 9:e1003514. doi:10.1371/journal.ppat.1003514
81. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology (2012) 56:2060-70. doi:10.1002/hep.25897
82. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 142:978-88. doi:10.1053/j.gastro.2011.12.055
83. Israelow B, Narbus CM, Sourisseau M, Evans MJ. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology (2014) 60(4):1170-9. doi:10.1002/hep.27227
84. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 79:3851-4. doi:10.1128/JVI.79.6.3851-3854.2005
85. Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, et al. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother (2013) 57:1312-22. doi:10.1128/AAC.02239-12
86. Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, et al. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads. Hepatol Res (2011) 41:126-32. doi:10.1111/j.1872-034X.2010.00750.x
87. Muir AJ, Shiffman ML, Zaman A, Yoffe B, De La Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 52:822-32. doi:10.1002/hep.23743
88. Ramos EL. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res (2010) 30:591-5. doi:10.1089/jir.2010.0066
89. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 29:4841-51. doi:10.1128/MCB.00224-09
90. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo. Hepatology (2011) 53:1154-63. doi:10.1002/hep.24189
91. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 461:399-401. doi:10.1038/nature08309
92. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 461:798-801. doi:10.1038/nature08463
93. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 139(120-129):e118. doi:10.1053/j.gastro.2010.04.013
94. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 41:1100-4. doi:10.1038/ng.447
95. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 41:1105-9. doi:10.1038/ng.449
96. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 138(1345):1338-45. doi:10.1053/j.gastro.2009.12.056
97. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, et al. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations. J Gen Virol (2011) 92:1071-81. doi:10.1099/vir.0.029124-0
98. di Iulio J, CiuffiA, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, et al. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology (2011) 53:1446-54. doi:10.1002/hep.24263
99. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 210:1109-16. doi:10.1084/jem.20130012
100. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 158:235-45. doi:10.7326/0003-4819-158-4-201302190-00003
101. Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM, et al. Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn (2011) 13:446-51. doi:10.1016/j.jmoldx.2011.03.008
102. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-DeltaG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis (2014) 209:350-4. doi:10.1093/infdis/jit433
103. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 52:1888-96. doi:10.1002/hep.23912
104. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One (2011) 6:e26620. doi:10.1371/journal.pone.0026620
105. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 139:499-509. doi:10.1053/j.gastro.2010.04.049
106. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol (2014) 15:72-9. doi:10.1038/ni.2758
107. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med (2009) 15:31-3. doi:10.1038/nm.1902
108. Estrabaud E, Lapalus M, Broet P, Appourchaux K, De Muynck S, Lada O, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol (2014) 88:6394-402. doi:10.1128/JVI.00016-14
109. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2010) 327:198-201. doi:10.1126/science.1178178
110. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2011) 140:1021-31. doi:10.1053/j.gastro.2010.11.039
111. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLoS One (2013) 8:e84026. doi:10.1371/journal.pone.0084026
112. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 317:944-7. doi:10.1126/science.1143767
113. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 41:591-5. doi:10.1038/ng.348
114. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis (2010) 202:1749-53. doi:10.1086/657146
115. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 107:4417-23. doi:10.1182/blood-2005-10-4129
116. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol (2004) 76:314-21. doi:10.1189/jlb.0204117
117. Egli A, Santer DM, O'Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect (2014) 3:e51. doi:10.1038/emi.2014.51